Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0036341 (schizophrenia)
 60,220 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

According to the psycho-pharmacological characteristics, indications, counterindications and side-effects of fluophenazine dihydrochloride, the authors present the results of a simple-blind study of Lyorodin--Jenapharm in a series of 30 in-patients of both sexes, aged between 30 and 65 years. Nosologically, there were cases of schizophrenia and post-process states, delirious hallucinatory syndromes of involution and asthenodithymic syndromes. The drug under the form of pills of 1 and 4 mg was given at average doses of 2-4 mg up to 6-10 mg for 28 days under clinical surveillance and laboratory tests. The estimation of the clinical results revealed the improvement of the symptoms in all investigated cases, a favourable evolution, low incidence and intensity of its side-effects, good tolerance and clinical efficacy comparable to that of Lyogen.
 ...
PMID:[Clinical observations on treatment with flufenazin dihydrochloride (Lyorodin--Jenapharm)]. 263 70

According to the indications of fluphenazin decanoate in the long-term treatment in schizophrenia the authors analyse the findings of a simple blind study of Lyorodin-depot on a sample of 20 inpatients. The drug was administered at intervals of 21 days for 18 weeks under clinical surveillance. The method consisted of patients' follow-up on an itemized card, psychological checkups and para-clinical investigations. The analysis of clinical findings reveals the amelioration of symptoms at the parameters accounted for, the favourable evolution low incidence of the side effects that confirms its clinical efficiency and tolerance.
 ...
PMID:[Clinical observations of treatment with Lyorodin-depot (Jenapharm)]. 270 35

Developed the present study in conjunction with a project that evaluated the psychiatric diagnosis of schizophrenia (Landmark, 1982; Landmark & Leslie, 1982). This design, which included 13 different interview systems for diagnosing schizophrenic disorders, allowed for an in-depth analysis of the Whitaker Index of Schizophrenic Thinking (WIST). Eighty-five outpatients who were receiving long-term chemotherapy for schizophrenia at the Moditen Clinic of London Psychiatric Hospital were reassessed individually using each of the 13 systems, following a clinical interview format, and the WIST. Major statistical analysis evaluated the concurrent validity and discriminatory efficiency of the WIST in comparison to the 13 systems. The WIST was found to show a consistently high agreement with each of the 13 systems for an average WIST discriminatory efficiency of 70%. The WIST is suggested as a practical, easily administered, diagnostic tool that performs well in comparison to the interview systems.
 ...
PMID:The Whitaker Index of Schizophrenic Thinking (WIST) and thirteen systems for diagnosing schizophrenia. 674 68

This study examined substance use among a group of 37 schizophrenia patients participating in a year-long fluphenazine decanoate (FD; Prolixin) dosage reduction study (Inderbitzin et al. (1994) Am. J. Psychiatry 151, 1753-1759). Ten (50%) of the 20 FD dose-reduced patients, and 6 (35%) of the 17 control group patients were identified as substance users. The dose-reduced and control groups did not differ significantly in substance use. We examine here the 37 patients regrouped by substance users (n = 16) versus non-users (n = 21) to determine the effects of substance use. In addition to identifying substance users and types of substances used, we hypothesize that substance users differ demographically from non-users, have worse symptomatology, worse compliance, higher rates of relapse, and therefore, can confound studies. Clinical and demographic data were obtained. At least half of the substance users were using alcohol or cocaine. The substance use group had a significantly higher severity of illness score on the BPRS at study onset. We found no significant differences between the two groups on other rating scales. The non-use group lived more independently, and the substance use group was younger. The substance use group had nearly twice as many hospitalizations in the 2 years prior to the study, a greater rate of missed appointments in the year before and during the study, and 4 times as many relapses during the year of the study than the non-use group. The key finding was that among 9 of the 37 patients who relapsed in the year of the study, 7 of the 9 had a history of substance use. Substance use was found to be a better predictor of relapse and hospitalization than gradual 50% dosage reduction of FD in the related study. Substance use among schizophrenia patients is a major complicating factor.
 ...
PMID:Substance use: a powerful predictor of relapse in schizophrenia. 879 2